TAVR (TAVI)
CTSNet hosted a webinar on September 15, 2026, titled “The TAVR Heart Team in 2026: Navigating the CMS Decision,” featuring leading surgeons Tom B. Nguyen, Michael Mack, and Tsuyoshi Kaneko, and cardiologist Martin B. Leon....
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with David Waller, Chair of the EACTS Emphysema Taskforce and Director of the EACTS Fundamentals Course in Thoracic Surgery, about...
In this discussion, CTSNet Senior Editor—Education Vincent Gaudiani, a Clinical Associate Professor of Cardiothoracic Surgery at Stanford University in Stanford, California, USA, and Chad Rammohan, an interventional and structural cardiologist...
This talk features Joseph Zacharias, a consultant cardiothoracic surgeon at the Lancashire Cardiac Center in Blackpool, England, delivering a presentation on “Can the Endoscope ‘Challenge’ the Catheter?” at the Endoscopic...
CTSNet hosted a webinar on September 15, 2026, titled “The TAVR Heart Team in 2026: Navigating the CMS Decision,” featuring leading surgeons Tom B. Nguyen, Michael Mack, and Tsuyoshi Kaneko,...
This article studied the use of both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) in patients with low-flow, low-gradient aortic stenosis, including both classical and paradoxical...
Transcatheter aortic valve implantation (TAVI) has emerged as the treatment of choice for symptomatic severe aortic stenosis (AS) across the whole surgical risk spectrum. Current European guidelines recommend surgical aortic...
Women with severe symptomatic aortic stenosis are underrepresented in clinical trials. The Randomized Research in Women All Comers with Aortic Stenosis (RHEIA) trial investigates the balance of benefits and risks...
The Evolut Low Risk trial demonstrated that transcatheter aortic valve replacement (TAVR) was noninferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at two years. In...
The treatment of aortic valve disease has evolved, and it is expected that TAVR will be available to most patients in the next few years. However, TAVR with a bioprosthesis...
This study compared outcomes between patients undergoing valve-in-valve transcatheter aortic valve replacement (ViV TAVR) and redo surgical aortic valve replacement (redo SAVR) using a retrospective analysis of institutional databases, which...
The EARLY TAVR trial investigators randomly assigned patients with asymptomatic severe aortic stenosis to undergo either early transfemoral transcatheter aortic valve replacement (TAVR) or clinical surveillance. The primary end point...
The role of transcatheter aortic valve replacement (TAVR) for the treatment of aortic stenosis in the pre- and post-lung transplant population is limited. This specific patient population is considered high...

